EpiPanelDxPLUS adds to Lineagens expanding menu of diagnostic tests for children with developmental disorders and provides an offering designed specifically for patients that have experienced seizures or other epilepsy-related symptoms
SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the release of EpiPanelDxPLUS by its diagnostics services business, Lineagen. The new laboratory developed test (LDT) and associated clinical support bolsters Lineagens diagnostic services for physicians providing care for pediatric patients with neurodevelopmental disorders (NDDs). EpiPanelDxPLUS is based on a proprietary panel of 223 genes associated with epilepsy-related conditions, more genes than typically found on epilepsy panels available from other service providers and customized for Lineagens core market of neurodevelopmental disorders.
Epilepsy refers to an array of neurological disorders characterized by involuntary seizures and affects approximately 1.2% of the population, or 3.4 million people, in the United States. It is frequently comorbid with other NDDs of childhood development, including intellectual disability and autism spectrum disorder and also can co-occur with neuro-behavioral disorders such as attention deficit hyperactivity disorder (ADHD). Collectively, NDDs represent the most common form of developmental disorder with an estimated prevalence of 1 out of 6 children affected in industrialized countries. Lineagens current menu of FirstStepDx PLUS chromosomal microarray and NextStepDx PLUSwhole exome sequencing offers leading molecular diagnostic tests designed to help pediatricians and pediatric neurodevelopmental specialists manage their patients with NDDs. Offering such physicians a test for epilepsy allows Lineagen to more comprehensively serve their needs.
Identifying the underlying genetic variants that may explain the underlying cause of seizures is extremely important because it informs multiple aspects of clinical care, said Alka Chaubey, PhD, Chief Medical Officer of Bionano Genomics. This test allows for personalized treatment of the patient, can predict the recurrence risk for other members of the family, and ends the diagnostic odyssey, which for many families can mean years of doctor visits, invasive tests, and failed or even harmful treatments.
EpiPanelDxPLUS is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures, and has an expected 30% diagnostic yield. Lineagen also offers testing to the parents of the patients. By including the analysis of the genomes of one or both biological parents of the patient from the start, it is possible to increase the detection rate of disease-causing variants and inform on recurrence risk for the family. EpiPanelDxPLUS has been curated based on thorough literature review and includes genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen.
The use of a targeted gene panel such as EpiPanelDxPLUS fits the testing strategy that is recommended by the American Academy of Neurology and complements existing genetic tests offered by Lineagen such as FirstStepDx PLUS chromosomal microarray and NextStepDx PLUS whole exome sequencing, which are recommended for patients who show a wider array of neurological symptoms. To help tailor medical management, Lineagen also offers pharmacogenomic testing which includes certain genes that are responsible for the metabolism of important anti-epileptic or anticonvulsant drugs prescribed for epilepsy.
We already have a depth of knowledge on epilepsy genetics, added Dr Chaubey. We recently tested a 3-year-old girl with muscle spasms and seizures, as well as her parents, and identified a mutation in the SLC2A1 gene. Based on these results, the doctor was able to treat the child with a simple ketogenic diet and over-the-counter supplementation. If she had instead been treated with barbiturates, at one time a standard treatment for epilepsy patients and now contraindicated in patients with this specific genetic condition, her seizures likely would have gotten worse. This case is one of many where results of a genetic test enabled the family and treating physician to significantly improve the quality of life of the child and family.
"Adding the EpiPanelDxPLUS test to Lineagens menu is a critical step forward in our plan for Lineagen to grow and continue supporting the physicians who rely on them," said Erik Holmlin, PhD, Chief Executive Officer of Bionano Genomics. "This test also forms the basis of how we envision incorporating the Saphyr system for comprehensive structural variation analysis into an improved diagnostic testing approach for epilepsy. In its current form, the EpiPanelDx test uses next generation sequencing (NGS) to identify single nucleotide variants and for evidence of gene deletion or duplication in 223 genes. Deletions and duplications are examples of structural variations (SVs) that NGS can detect with reasonable sensitivity, but otherwise, NGS is essentially blind to certain SVs that Saphyr detects with ease. We believe using Saphyr in conjunction with NGS can enable later generations of EpiPanelDxPLUS to have potentially higher diagnostic yields by identifying more genetic variations, which may in turn diagnose more patients, and be a unique combination in the industry.
The EpiPanelDxPLUS diagnostic test is available now with full clinical support including genetic counselling. More details on the diagnostic test are available at https://lineagen.com/epipanel/
About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visitwww.bionanogenomics.com or http://www.lineagen.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, intended use of Lineagens tests, including NextStepDX, anticipated benefits of expanded test offerings from Lineagen, anticipated improvements in patient treatment and diagnosis attributable to Lineagens tests, potential combinations or other uses of the Saphyr system in conjunction with Lineagens tests and any improvements in diagnostic testing generated from such uses. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; failure of our products to achieve the stated objectives or anticipated benefits; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com
Media Contact:Darren Opland, PhD+1 (617) 733-7668darren@lifescicomms.com
Follow this link:
Bionano Genomics Expands Its Diagnostic Testing Menu with Launch of Lineagen's EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions...
- Heredity - DNA, Genes, Inheritance | Britannica - January 6th, 2025
- Comparing Genetics and Molecular Genetics: What's the Difference? - December 19th, 2024
- Standards and guidelines for the interpretation of sequence ... - PubMed - December 19th, 2024
- Chapter 12: Techniques of Molecular Genetics - Biology LibreTexts - December 19th, 2024
- 8.S: Techniques of Molecular Genetics (Summary) - December 19th, 2024
- Master of Science Computational Biology and Quantitative Genetics - December 19th, 2024
- Pitt Researchers Lead Group that Calls for Global Discussion About Possible Risks from Mirror Bacteria - Pitt Health Sciences - December 19th, 2024
- Molecular Genetics Testing - StatPearls - NCBI Bookshelf - November 16th, 2024
- Working with Molecular Genetics (Hardison) - Biology LibreTexts - November 16th, 2024
- Molecular Underpinnings of Genetic and Rare Diseases: From ... - Frontiers - November 16th, 2024
- The molecular genetics of schizophrenia: New findings promise new insights. - November 16th, 2024
- 8: Techniques of Molecular Genetics - Biology LibreTexts - September 4th, 2024
- 1.5: Molecular Genetics - Biology LibreTexts - September 4th, 2024
- Molecular genetics made simple - PMC - National Center for ... - September 4th, 2024
- 4 Introduction to Molecular Genetics - University of Minnesota Twin Cities - September 4th, 2024
- Molecular genetics - Definition and Examples - Biology Online - September 4th, 2024
- A Detailed Look at the Science of Molecular Genetics - KnowYourDNA - September 4th, 2024
- Molecular Genetics | NHLBI, NIH - September 4th, 2024
- Molecular biology - Wikipedia - September 4th, 2024
- Genetics, Molecular & Cellular Biology Admissions - September 4th, 2024
- Researchers map 50,000 of DNAs mysterious knots in the human genome - EurekAlert - September 4th, 2024
- Artificial selection of mutations in two nearby genes gave rise to shattering resistance in soybean - Nature.com - September 4th, 2024
- Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany - Marketscreener.com - April 7th, 2023
- Molecular Genetics and Metabolism | Journal - ScienceDirect - December 11th, 2022
- People don't mate randomly but the flawed assumption that they do is an essential part of many studies linking genes to diseases and traits - The... - November 25th, 2022
- Molecular and Cell Biology and Genetics - Master of Science / PhD ... - October 7th, 2022
- NIPD Genetics: Leading Genetic Testing Company - October 7th, 2022
- Skeletal Biology and Regeneration Students Recognized For Research Excellence - UConn Today - University of Connecticut - October 7th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 7th, 2022
- Every Body's Talking at Them: an Interview with Jon Lieff - CounterPunch - October 7th, 2022
- TriBeta invites students to explore opportunities to work with faculty at research fair on Oct. 11 - Ohio University - October 7th, 2022
- Genetics: the Vatican Does Not Intend to Be Behind the Times - FSSPX.News - October 7th, 2022
- Yield10 Bioscience Appoints Willie Loh, Ph.D., to the Board of Directors - citybiz - October 7th, 2022
- Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com - October 7th, 2022
- Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel - Yahoo Finance - October 7th, 2022
- UTHSC Researcher Co-Leads Study of Genes that Modulate Aging, Lifespan - UTHSC News - UTHSC News - October 7th, 2022
- GATC Health Investor Conference to Feature First Public Demonstration of Its AI Platform's Drug Discovery Capabilities - PR Newswire - October 7th, 2022
- Three Professors Conferred Tenure and Eleven Promoted - Wesleyan Argus - October 7th, 2022
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 7th, 2022
- Dalhousie to present exhibition celebrating Gerhard Herzberg and his legacy - Dal News - October 7th, 2022
- Why Some People Should Rethink Their Morning Cup Of Coffee - Health Digest - October 7th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 7th, 2022
- UofL researchers lead the call to increase genetic diversity in immunogenomics - uoflnews.com - July 6th, 2021
- In Brief This Week: Foundation Medicine, Myriad Genetics, Genetron Health, and More - GenomeWeb - July 6th, 2021
- More filling? Tastes great? How flies, and maybe people, choose their food - Yale News - July 6th, 2021
- Genetic mapping of subsets of patients with fragile X syndro | TACG - Dove Medical Press - July 6th, 2021
- What is The Babydust Method? Danielle Lloyd swears method helped her conceive girl - The Mirror - July 6th, 2021
- Datar Cancer Genetics joins hands with US based Iylon Precision Oncology to offer personalized Precision Oncology cancer treatment solutions - PR Web - July 6th, 2021
- Mapping a pathway to competitive production - hortidaily.com - hortidaily.com - July 6th, 2021
- Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. - Physician's Weekly - July 6th, 2021
- Global Genomics Market | Rising Incidence of Chronic and Genetic Diseases are Key Factors to Grow Market During 2021-2029 | 23andMe, Agilent... - July 6th, 2021
- The Babydust Method Danielle Lloyd used to conceive a girl after four sons and how it works - RSVP Live - July 6th, 2021
- In the beginning science and faith - The Irish Times - June 24th, 2021
- Ancient Maya Maintained Native Tropical Forest Plants around Their Water Reservoirs | Archaeology - Sci-News.com - June 24th, 2021
- Local foundation awards $1.25 million to MIND Institute to study rare genetic condition - UC Davis Health - June 24th, 2021
- Xlife Sciences AG: Collaboration with the University of Marburg - Yahoo Finance - June 24th, 2021
- Genetics diagnostics in India is on the verge of transformation: Neeraj Gupta, Founder and CEO of Genes2me - The Financial Express - June 24th, 2021
- Precision Medicine: Improving Health With Personalized Solutions - BioSpace - June 24th, 2021
- Half of Portland areas 22 top National Merit winners hail from just 2 schools - OregonLive - June 24th, 2021
- Investing in stem cells, the building blocks of the body - MoneyWeek - June 24th, 2021
- New study finds low levels of a sugar metabolite associates with disability and neurodegeneration in multiple sclerosis - Newswise - May 14th, 2021
- Cernadas-Martn Is a Champion for Marine and Human Diversity | | SBU News - Stony Brook News - May 14th, 2021
- Four Penn Faculty: Election to the National Academy of Sciences - UPENN Almanac - May 14th, 2021
- Is there a difference between a gene-edited organism and a 'GMO'? The question has important implications for regulation - Genetic Literacy Project - May 14th, 2021
- 5 Students Inducted Into American Society for Biochemistry and Molecular Biology Honor Society - Wesleyan Connection - May 14th, 2021
- The Science of Aliens, Part 2: What Kind of Genetic Code Would Extraterrestrials Have? - Air & Space Magazine - May 14th, 2021
- UT Austin Faculty Member Receives 2021 Piper Professor Award - Office of the Executive Vice President and Provost - UT News | The University of Texas... - May 14th, 2021
- Distinguished University of Birmingham plant scientist elected to the Royal Society - University of Birmingham - May 14th, 2021
- Double Hoo Research: Undergrads and Grads Team Up to Create Knowledge - University of Virginia - May 14th, 2021
- Global Genetic Testing Market Top Countries Analysis and Manufacturers With Impact of COVID-19 | 2021-2028 Detail Analysis focusing on Application,... - May 14th, 2021
- Morag Park named to the Order of Quebec - McGill Reporter - McGill Reporter - May 14th, 2021
- Third Rock Ventures Launches Flare Therapeutics With $82 Million Series A - BioSpace - May 14th, 2021
- The Royal Society announces election of new Fellows 2021 - Cambridge Network - May 14th, 2021
- Researchers Decode the "Language" of Immune Cells - Technology Networks - May 14th, 2021
- RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map -... - May 14th, 2021
- Mice Sperm Sabotage Other Swimmers With Poison | Smart News - Smithsonian Magazine - February 14th, 2021
- Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth - Newswise - February 14th, 2021
- Devious sperm 'poison' their rivals, forcing them to swim in circles until they die - Livescience.com - February 14th, 2021
- More needs to be done to find and fight COVID-19 variants, says Colorado researcher - FOX 31 Denver - February 14th, 2021
- Selfish sperm genes 'poison' the competition for the win - Big Think - February 14th, 2021